Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use

A legfontosabb adatok

Ki végzi
Ellen Herbst
Hol
San Francisco (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
41 fő vett részt
Kezdés
2021. aug. 25.
Befejezés
2025. jún. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • N-Acetyl cysteine
  • Placebo comparator
  • Cognitive behavioral therapy (CBT)
A regiszteradat frissítve
2026. augusztus 11.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants will be male and female smokers ages 18 and over who: 1) have smoked 2 cigarettes per day in 15 of the past 30 days, or an average of 1 cigarettes per day for the past 30 days; 2) endorse the use of cannabis within the past 30 days, reported by Timeline Follow-Back (TLFB), and have positive urine tetrahydrocannabinol (THC) at Week 0 or up to 30 days prior; 3) meet criteria for tobacco use disorder (TUD) in the past 12 months per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), assessed by medical record review and clinical assessment; and 4) consent to receive interventions to stop smoking cigarettes and reducing cannabis use. Although co-users can use tobacco and cannabis simultaneously (i.e. in "spliffs") and other forms of nicotine and tobacco, participants must smoke combustible cigarettes that are not mixed with cannabis on a daily basis to participate. Individuals of childbearing potential (ages 18-55) must have a negative urine pregnancy test at the time of screening. Individuals who have been prescribed bupropion for depression, not smoking cessation, are eligible to participate in this study. All participants must be California residents (Veterans enrolled in VA healthcare in another state are eligible)

Ki nem vehet részt

  • Psychotic disorders, bipolar disorder, neurocognitive disorder, or other psychiatric or medical conditions judged by the PI to be unstable in the past 30 days, based on screening results and/or medical record review. 2) Concurrent participation in another pharmacological tobacco cessation study. 3) Individuals who are pregnant or lactating. 4) Non-study NAC use at enrollment or at any time during the study period. 5) Use of medications for TUD (NRT, bupropion, or varenicline) at enrollment or at any time during the study period. 6) A suicide attempt or suicidal ideation with intent in the 30 days prior to enrollment. 7) Non-residents of California or Veterans in another state who are not enrolled in VA healthcare

Helyszínek itt: Egyesült Államok

  • San Francisco Veterans Affairs Medical CenterSan Francisco, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Tobacco and cannabis co-use is a common and growing public health problem, especially in states that have legalized cannabis. There are no pharmacologic treatments for co-occurring tobacco and cannabis use. Co-use may make quitting either substance more difficult, given the synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared cues reinforcing co-use. N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing tobacco and cannabis craving and use.

A vizsgálat 2 csoportja

  • N-acetyl cysteine (NAC) & cognitive behavioral therapyA vizsgált kezelés

    N-acetyl cysteine (NAC) \& cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.

    Kezelés: N-Acetyl cysteine és Cognitive behavioral therapy (CBT)

  • Placebo Comparator: Placebo & cognitive behavioral therapyPlacebo, összehasonlításként

    Placebo comparator \& cognitive behavioral therapy arm consists of 30 regular cigarette smokers and cannabis users with current TUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and cannabis use.

    Kezelés: Placebo comparator és Cognitive behavioral therapy (CBT)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use: A Randomized Controlled Trial
Publikációk
A regiszteradat frissítve
2026. augusztus 11.